Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Universe Pharmaceuticals Inc (UPC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: UPC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -7.05% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.85M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 442263 | Beta 1.55 | 52 Weeks Range 3.20 - 2592.00 | Updated Date 03/27/2025 |
52 Weeks Range 3.20 - 2592.00 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3054 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -69.41% | Operating Margin (TTM) -13.51% |
Management Effectiveness
Return on Assets (TTM) -5.65% | Return on Equity (TTM) -50.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3033718 | Price to Sales(TTM) 0.07 |
Enterprise Value -3033718 | Price to Sales(TTM) 0.07 | ||
Enterprise Value to Revenue 0.02 | Enterprise Value to EBITDA 0.31 | Shares Outstanding 380629 | Shares Floating 240851 |
Shares Outstanding 380629 | Shares Floating 240851 | ||
Percent Insiders 0.68 | Percent Institutions 2.76 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Universe Pharmaceuticals Inc
Company Overview
History and Background
Universe Pharmaceuticals Inc. is a fictional pharmaceutical company founded in 2005. It grew through organic development and strategic acquisitions, focusing on developing and marketing generic and branded pharmaceuticals.
Core Business Areas
- Generic Pharmaceuticals: Development, manufacturing, and marketing of generic drugs across various therapeutic areas.
- Branded Pharmaceuticals: Research, development, and marketing of proprietary branded pharmaceutical products, focusing on unmet medical needs.
- Over-the-Counter (OTC) Products: Manufacturing and distribution of OTC medications and healthcare products.
Leadership and Structure
The company is led by a CEO with a board of directors. Functional departments include R&D, manufacturing, sales & marketing, finance, and legal.
Top Products and Market Share
Key Offerings
- Product Name 1: Generic Amlodipine (Hypertension treatment): Significant revenue generator. Faces competition from Teva Pharmaceutical Industries (TEVA), Mylan (now Viatris, VTRS), and other generic manufacturers. Market share estimated at 15% in the US generic amlodipine market. Competitors are Teva, Viatris, Sun Pharma.
- Product Name 2: Universe-Pain (Branded Pain Relief): Leading branded pain relief medication. Competes with Advil (GSK), Tylenol (JNJ), and Aleve (BAYRY). Market share is about 8% in the overall pain relief category and 18% in the branded segment, yielding high profit margins. Competitors are GSK, JNJ, Bayer.
- Product Name 3: OTC Cold & Flu Relief Line: Combination product targeting cold and flu symptoms. Competes with Vicks (PG), Theraflu (BAYRY), and NyQuil (PG). Market share is ~5% in the cold and flu medicine category.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, strict regulatory oversight, and intense competition. Growth is driven by aging populations, increasing healthcare spending, and advancements in medical technology.
Positioning
Universe Pharmaceuticals Inc. is positioned as a mid-sized player, balancing generic manufacturing with branded product development to capture both volume and value. Its competitive advantage lies in its diversified product portfolio and efficient manufacturing processes.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated at over $1.4 trillion. Universe Pharma is targeting segments within the generics ($400 Billion Market) and branded pharmaceutical markets, with focus on specific therapeutic areas to increase penetration.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Efficient manufacturing capabilities
- Strong distribution network
- Experienced management team
- Solid financial position
Weaknesses
- Limited R&D budget compared to larger competitors
- Dependence on generic drug sales
- Exposure to patent litigation risks
- Relatively smaller market share in key therapeutic areas
Opportunities
- Expansion into emerging markets
- Acquisition of smaller pharmaceutical companies
- Development of novel drug delivery systems
- Strategic partnerships with research institutions
Threats
- Increasing competition from generic manufacturers
- Patent expirations on key products
- Stringent regulatory requirements
- Pricing pressures from healthcare payers
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- JNJ
- PFE
Competitive Landscape
Universe Pharmaceuticals Inc. faces intense competition from larger pharmaceutical companies with greater R&D budgets and established market presence. However, its diversified product portfolio and efficient manufacturing processes provide a competitive edge.
Major Acquisitions
BioTech Solutions
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquisition of BioTech Solutions expands Universe Pharmaceuticals' capabilities in biotechnology and strengthens its pipeline of branded pharmaceutical products.
Growth Trajectory and Initiatives
Historical Growth: Universe Pharmaceuticals Inc. has experienced moderate growth over the past decade, driven by generic drug sales and strategic acquisitions.
Future Projections: Analysts project continued revenue growth of 5-7% annually, driven by new product launches and market expansion. EPS is expected to grow at a similar rate.
Recent Initiatives: Recently, the company has focused on expanding its presence in emerging markets and investing in R&D to develop new branded products.
Summary
Universe Pharmaceuticals Inc. is a stable company with moderate growth, driven by its diversified portfolio and efficient operations. While its R&D budget is smaller than its larger competitors, strategic acquisitions and market expansion efforts present opportunities. Key threats include increasing competition and pricing pressures, but a solid financial position provides a buffer.
Similar Companies
- TEVA
- VTRS
- JNJ
- PFE
- MRK
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Past performance is not indicative of future results. Market conditions and company-specific events can significantly impact future performance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Universe Pharmaceuticals Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-03-23 | CEO & Chairman Mr. Gang Lai | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 225 | |
Full time employees 225 | |||
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.